Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the combination of fluticasone propionate and UV-A was much more effective for vitiligo repigmentation than either treatment used alone, with no significant adverse effects reported.

In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.

This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.

This study concluded that a combined once-daily solution of 5% minoxidil and 0.01% tretinoin is as effective and safe as the conventional twice-daily 5% minoxidil application for treating androgenetic alopecia in men.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

In this study, the combination of pulse intravenous corticosteroids and methotrexate was associated with positive hair regrowth in severe alopecia areata patients, with half achieving total regrowth.

This study found that a combination of low-fluence Q-switched 1064 nm Nd:YAG laser, hydroquinone cream, and oral tranexamic acid showed promising results for Riehl’s melanosis in Asian patients, with no serious adverse events reported.

This review reports that 100 mg/day spironolactone improved hair growth more than placebo and was more effective in reducing hair growth than finasteride and low-dose cyproterone acetate, but its effectiveness for acne remains unclear due to small sample sizes.

In this study, the combination of arsenic toxicity and hypoxia in Arabidopsis thaliana altered root development through stress-specific root growth phenotypes and changes in phosphate starvation response, energy metabolism, and redox signaling.

This study observed that methotrexate combined with low- to moderate-dose oral corticosteroids may effectively treat severe alopecia areata, though long-term maintenance is often necessary due to relapse after tapering.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This study suggests that a mixture of 5‐ALA and iron ion significantly improved hair growth in mice, comparable to minoxidil, without promoting keratinocyte or fibroblast proliferation in vitro.

This study found that using a combination of iontophoresis and liposomal delivery facilitated the effective intradermal administration of superoxide dismutase in rats, reducing oxidative skin damage from UV exposure.

This open-label study suggests that combining valproate, lamotrigine, and a benzodiazepine can significantly reduce the frequency of epileptic drop attacks in patients with generalized or multifocal epilepsies.

In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.

This study found that DNA hypermethylation was present in melasma lesions, and treatments with sunscreen, niacinamide, and retinoic acid were associated with decreased methylation and clinical improvement.

This study found that introducing warning symbols and educational programs significantly reduced the erroneous crushing of medications in nursing homes.

This study concluded that high-dose oral therapy with L-cystine, gelatin, and vitamin A significantly improved hair growth indicators in patients with diffuse hair loss, with no systemic side effects observed.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

This study found that an injectable hydrogel dressing with silver nanoparticles showed promise in healing MRSA-infected wounds by reducing inflammation, supporting tissue regeneration, and maintaining prolonged antibacterial activity, highlighting its potential as an effective treatment strategy.

This meta-analysis suggests that combining Kang-ai injection with platinum-based chemotherapy may improve tumor response, performance status, immune functions, and reduce adverse reactions in patients with advanced non-small cell lung cancer.

This study found that coloring white facial hair is an effective and feasible adjunct to intense pulsed light therapy for hair removal, with similar efficacy between using black eyeliner and black hair dye.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

This article discusses the role of external beam radiotherapy as a primary treatment method for cancer and reports no new clinical findings.

This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.

This study observed that individuals with mixed ethnicity had hair that varied widely in shape and showed significant surface damage near the root, differing from monoracial hair characteristics.

This meta-analysis found that combined BRAF and MEK inhibitor treatment in melanoma patients is linked to increased all-grade rash but reduced risks of several other dermatological toxicities compared to BRAF inhibition alone.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This study suggests that adding imiquimod to diphenylcyclopropenone treatment significantly improves outcomes for alopecia areata patients who initially do not respond to diphenylcyclopropenone alone.